View Source

The Week in Business: Where Are the Jobs?

Good morning and happy Mother’s Day. (Hi, mom!) Here’s the news you need to know for the week ahead in business and tech. — Charlotte Cowles

Credit…Giacomo Bagnara

Economists expected the April jobs report to be full of great news — lower unemployment, robust hiring, confetti! And by most measures, they were disappointed. The pace of hiring actually slowed, and the unemployment rate rose slightly, to 6.1 percent, for the first time in a year. What’s going on? It’s complicated. Some lawmakers say that the government’s supplemental unemployment benefits are discouraging people from re-entering the work force, particularly in lower-wage positions. Others point to the millions of Americans who aren’t able to work because they’re managing child care, as many schools still aren’t yet back to normal operations. Either way, the country’s economic recovery isn’t going to be simple.

It’s been five months since Facebook barred former President Donald J. Trump indefinitely for his role in inciting the Jan. 6 insurrection at the Capitol. As for when to allow him back, the platform kicked the question over to its independent oversight board, a group of about 20 academics, human rights leaders and political figures from around the globe. Last Wednesday, the group upheld Facebook’s ban, but ruled that the company had to establish a clearer policy for it. Facebook now has six months to make a long-term decision about Mr. Trump’s account and create community standards that justify it.

are divorcing. Their eponymous foundation has an endowment of about $50 billion and spent over $1 billion to combat the coronavirus pandemic in the past year alone. The organization released a statement saying that the couple intends to remain co-chairs and trustees, and no changes are expected. Still, the divorce will affect their shared fortune, much of which has been pledged but not yet donated to the foundation. Mr. Gates, 65, co-founded Microsoft and is one of the richest people in the world.

Credit…Giacomo Bagnara

President Joseph R. Biden will hold a meeting with the four top House and Senate leaders, from both sides of the aisle, for the first time since taking office. House Speaker Nancy Pelosi, the Senate majority leader Chuck Schumer, and their Republican counterparts, Kevin McCarthy and Mitch McConnell, are expected to discuss Mr. Biden’s $4 trillion economic agenda and his plans to fund it by taxing the rich. Republican lawmakers have fought the proposals from day one. Sounds like a fun conversation.

Warren Buffett, the chief executive of Berkshire Hathaway, says inflation is rising. The price of building materials and other consumer goods is going up as demand grows and production costs increase. But the Federal Reserve has repeatedly encouraged investors not to fret. Is the economy going to overheat, with interest rates so low? Probably a bit. But slightly higher prices for a temporary period is in step with the Fed’s general aim for an inflation rate of 2 percent on average over time, to make up for exceptionally weak gains over the past several years.

The Biden administration has backed a temporary suspension of intellectual property rights for coronavirus vaccines, which would allow third-party drugmakers around the world to manufacture and distribute them to nations that need them. But the U.S. pharmaceutical industry is not happy about this, particularly those who hold the patents on these vaccines. (Pfizer alone generated $3.5 billion in revenue from its Covid-19 vaccine in the first three months of this year.) Representatives of the companies argue that suspending those patents will discourage future innovation and potentially decrease the safety standards of vaccine manufacturing and efficacy. Support from the White House does not guarantee that a waiver will happen, but it adds momentum.

View Source

Germany Is Seeing Virus Cases Go Down and Vaccinations Go Up

BERLIN — Dr. Peter Weitkamp placed an ad in eBay’s classifieds last week, offering appointments for an AstraZeneca vaccine — “free/to give away” — to anyone over 60. Many of his own patients didn’t want it, since the German government had spent months questioning the vaccine.

But within a day, his practice in Kirchlengern, in the western state of North Rhine-Westphalia, was inundated with calls from people seeking the remaining 80 to 90 doses, including some offering to drive in from out of state. Another family doctor got a similar response after setting up a drive-through vaccination center in a grocery store parking lot to administer AstraZeneca shots her that her own patients had rejected.

To the doctors, the response was proof that plenty of Germans were willing, even eager, for doses of AstraZeneca. Days later, the German government apparently agreed and relaxed previous restrictions that limited the AstraZeneca vaccine to certain age groups over concerns about rare but dangerous blood clots.

vaccine passport to make travel within the European Union easier and Germany’s upper house of Parliament moving to exempt the fully vaccinated from many restrictions — social distancing and wearing a mask will still be required of everyone — many Germans who qualified for an AstraZeneca shot were reluctant to get one. That was partly because the rival two-dose vaccine from BioNTech and Pfizer could be completed in only six weeks, whereas the recommended wait between shots for the AstraZeneca one was 12 weeks.

“We will make a lot more flexibility possible,” Mr. Spahn told the public television station WDR on Wednesday. “Many people want to have their second shot earlier, with an eye on summer, and that is possible with Astra.”

The Lancet in February said the vaccine provided protection of more than 80 percent if the second shot was administered after 12 weeks, while after less than six weeks, it provided only 55 percent protection.

“The considerable damage to the image of AstraZeneca’s vaccine, which is still unjustified, is also because of the uncertainty caused by the disastrous communication of its possible side effects by politicians and authorities among the population,” said Ulrich Weigeldt, chairman of the German Association of Family Physicians.

German health authorities initially limited its application to younger adults because there wasn’t enough information on how older adults responded. Then they suspended it for several weeks because of reports of cases of blood clots accompanied by low platelet counts, before reintroducing it but only for individuals older than 60.

began reopening retail shops and outdoor dining, at a time when Germans were still wrangling over the terms of a new lockdown. That included nightly curfews to slow a surging third wave of the virus and a cumbersome vaccine sign-up system riddled with bureaucratic hurdles, and overtaxed hotlines.

“The British of course are all laughing, ‘Oh, the Germans again,’” said Henrike Thalenhorst, who is completing her residency in the office of Dr. Weitkamp, who offered the AstraZeneca appointments on eBay. “They are thinking, ‘While they are filling out six pieces of paper and waiting for an appointment we are all vaccinated with Astra and hitting the pubs.’”

But while AstraZeneca’s links to Britain made it a source of local pride, for Germans, similar sentiments surround the BioNTech-Pfizer vaccine, which was developed by a start-up based in the western city of Mainz and known to some as “the Mercedes-Benz of vaccines.”

In a letter to the Neue Westfälische newspaper, one man described his decision to hold out against an offer of AstraZeneca as a matter of national pride. “As a not-yet-vaccinated 67-year-old German patriot,” wrote Lutz Schaal, from Bielefeld, “I am waiting for my BioNTech inoculation.”

Christopher F. Schuetze contributed reporting from Berlin and Megan Specia from London.

View Source

Covid-19 Live Updates: Pfizer Seeks Full F.D.A. Approval for Its Vaccine

their Covid-19 vaccine for use in people 16 and older. The vaccine is currently being administered to adults in America under an emergency use authorization granted in December.

The approval process is likely to take months.

The companies said in a statement on Friday that they had submitted their clinical data, which includes six months of information on the vaccine’s safety and efficacy, to the F.D.A. They plan to submit additional material, including information about the manufacturing of the vaccine, in the coming weeks.

“We are proud of the tremendous progress we’ve made since December in delivering vaccines to millions of Americans, in collaboration with the U.S. government,” Dr. Albert Bourla, Pfizer’s chief executive, said in the statement. “We look forward to working with the F.D.A. to complete this rolling submission and support their review, with the goal of securing full regulatory approval of the vaccine in the coming months.”

As of Thursday, more than 134 million doses of the vaccine had been administered in the United States, according to the Centers for Disease Control and Prevention. Full approval would allow Pfizer and BioNTech to market the vaccine directly to customers.

It could also make it easier for companies, government agencies and schools to require vaccinations. The Equal Employment Opportunity Commission said in December that employers could mandate vaccination, and legal experts have generally agreed.

Many companies have been hesitant to require the vaccines, especially while they have only emergency authorization, which is designed to be temporary. Some institutions, like the University of California and California State University systems, have said that they would do so only after a vaccine has full approval.

Full approval could also prompt the U.S. military, which has had low uptake of Covid-19 vaccines, to mandate vaccinations for service members.

If the F.D.A. grants full approval, it could also help raise confidence in the vaccine. The pace of vaccination has slowed in the United States in recent weeks, and a recent national survey indicated that most people in the country who planned to get the shots had already done so.

The agency is also expected to issue an emergency authorization for use of the Pfizer-BioNTech vaccine in 12- to 15-year-olds next week. The companies have said that they plan to file for emergency authorization for 2- to 11-year-olds in September.

Moderna plans to apply for full approval for its Covid-19 vaccine this month, the company said during its quarterly earnings call on Thursday.

Director of the Center for the National Center for Immunization and Respiratory Diseases Dr. Nancy Messonnier spoke in Washington in January 2020.
Credit…Amanda Voisard/Reuters

Dr. Nancy Messonnier, who famously warned the nation early last year that the coronavirus would upend their lives, resigned from her position at the Centers for Disease Control and Protection on Friday.

Dr. Messonnier’s resignation is effective May 14. She is taking on a new role as an executive director at the Skoll Foundation, a philanthropical organization based in Palo Alto, Calif., she told staff in an email on Friday.

Her exit may augur more changes at the agency. Reports have circulated for weeks that the C.D.C.’s new director, Dr. Rochelle Walensky, planned to completely reorganize the division Dr. Messonnier led.

“My family and I have determined that now is the best time for me to transition to a new phase of my career,” Dr. Messonnier wrote in the email to staff.

Dr. Messonnier began her career in public health in 1995 with a stint in the prestigious Epidemic Intelligence Service. She has since held a number of leadership posts in the C.D.C. Since 2016, she has served as director of the National Center for Immunization and Respiratory Diseases, the C.D.C. division responsible for managing influenza and other respiratory threats.

In late 2019, she became the agency’s lead in responding to the coronavirus, and initially shared a stage with President Trump at briefings about the coronavirus.

She fell out of favor with President Trump and sent stocks tumbling after she sounded a dire alarm about the coronavirus, saying it would disrupt the lives of every American.

“It’s not a question of if this will happen but when this will happen and how many people in this country will have severe illnesses,” she said on Feb. 25, just as Mr. Trump was boarding Air Force One in New Delhi for his flight home.

Soon after that, she stopped appearing at briefings of the White House and of the C.D.C.

Patients with Covid-19 in the emergency ward at the Holy Family hospital in New Delhi on Thursday.
Credit…Rebecca Conway/Getty Images

India’s worsening coronavirus outbreak has spread far outside its cities to rural areas with poor health care infrastructure and limited testing capacities, doctors and experts say.

One factor behind the surge of cases, they believe, is a series of recent campaign rallies held without social distancing.

The state of West Bengal, where Prime Minister Narendra Modi’s party lost an election last week after more than a month of campaigning to vast crowds, is recording the highest rate of positive coronavirus tests in the country. More than 31 percent of tests in the state are now coming back positive.

“There is a clear pattern here: States that went through elections and where large rallies were held are witnessing a huge rise in cases,” said Dr. Thekkekara Jacob John, a senior virologist in the southern state of Tamil Nadu.

In Uttar Pradesh, India’s most populous state, 1,028 new coronavirus cases and four deaths were recorded on March 26. On April 29, after campaigns for local village council elections were held, there were 35,104 cases and 288 deaths. A teachers’ union in the state said that 577 teachers and support staff members who were on duty as election workers had died of Covid-19.

The country’s cases as a whole have been skyrocketing since late March, from a seven-day average of more than 62,000 on March 31 to more than 385,000, according to the Our World in Data project at the University of Oxford. On Friday, the country reported more than 410,000 new daily infections, a record, and more than 3,900 deaths.

As the outbreak reaches new heights, India’s vaccination campaign has slowed down, marred by supply shortages and competition among states.

The official daily death in the country has stayed over 3,000 over the past 10 days, and experts say the numbers are much higher,.

The true scope of the outbreak remains hard to measure. Nationwide, India conducted about 1.9 million coronavirus tests on Thursday, an increase from about 1.2 million daily tests last month, but hardly enough to keep up with a daily caseload that has almost quadrupled in that time.

West Bengal, a state of 90 million people that has poor health care infrastructure and is under a partial lockdown, has carried out fewer than 60,000 coronavirus tests a day. That is one of the lowest rates in the country, according to data compiled by researchers at the University of Michigan.

Dr. Abhijeet Barua, a physician in Kolkata, the state’s capital, said that cases had exploded in every corner of the city and that infections were spreading quickly in the state’s rural areas. At his 10-bed clinic, two people have died every day over the past 15 days, Dr. Barua said.

“What is making things worse in Kolkata is that over 70 percent of the population lives in close contact,” he said, adding that he was receiving dozens of calls a day from patients seeking help. “You can’t isolate yourself, because it is so congested here.”

Mr. Modi has repeatedly refrained from imposing a nationwide lockdown. Instead nearly a dozen of India’s 28 states have imposed restrictions, though they are less stringent than the nationwide lockdown put in place last year.

Protective masks are worn in March in Tokyo, the host of this summer’s Olympic Games.
Credit…Noriko Hayashi for The New York Times

TOKYO — Japan on Friday extended a state of emergency in Tokyo and other regions until the end of May to contain a surge of coronavirus cases, casting further doubt on the country’s ability to safely host the Summer Olympics, which are scheduled to begin in 11 weeks.

Prime Minister Yoshihide Suga made the announcement at a meeting of the government’s coronavirus task force, saying that the measures were necessary because infections remain at a “high level, mainly in large cities.”

The announcement extends emergency measures imposed last month to two more prefectures, covering a total of six prefectures, including Tokyo and Osaka, that are together home to over a third of Japan’s 126 million people. Another eight prefectures will be under slightly looser restrictions.

The existing state of emergency, which were imposed to curb travel during the just-ended Golden Week holiday period and had been set to expire next week, have not slowed Japan’s fourth wave of coronavirus infections. In early March, the country recorded about 1,000 daily new. It is now recording nearly 6,000, according to a New York Times database.

Health officials say that they are seeing a growing number of cases of coronavirus variants spreading in the population, including at least 26 cases of the strain first detected in India. The authorities in Tokyo say that in four out of five cases found in the city, the infected person neither traveled abroad nor had close contact with someone who had.

The outbreak is stretching health care systems even in Japan’s biggest cities. On Thursday, there were 370 people being treated for serious cases of Covid-19 in Osaka, a prefecture of nine million people, more than the number of hospital beds available for seriously ill patients.

Japan, which has recorded more than 620,000 infections and 10,000 deaths since the start of the pandemic, has controlled the virus better than many countries. But the government has faced criticism for the sluggish pace of vaccinations, and for pledging to go ahead with the Tokyo Olympics, scheduled to begin on July 23, despite widespread public opposition.

Toru Hashimoto, a lawyer and a former governor of Osaka prefecture, said on a television show on Friday that Olympic organizers were ignoring the severity of Japan’s outbreak, and that it was inappropriate to continue holding pre-Olympic “test events” during the state of emergency, even though they are taking place without spectators.

“If the government wants to reduce the number of people in the city, it’s not a time when test events can be held,” Mr. Hashimoto said.

The government has imposed two previous states of emergency during the pandemic, although they are looser than the total lockdowns seen in many nations. The measures allow the prefectures to ask businesses to close or to restrict their hours, and to fine those that do not.

Under the extended state of emergency, people are asked not to go out for nonessential matters, especially after 8 p.m., and to refrain from traveling outside their prefectures. Karaoke parlors are asked to close, and restaurants requested not to serve alcohol, with fines of up to 300,000 yen, or $2,750, for noncompliance.

A vaccination center in Johannesburg in March.
Credit…Joao Silva/The New York Times

A global debate is heating up over how to get Covid-19 vaccines to the nations most in need.

The United States is supporting an effort to suspend intellectual property protections on Covid-19 vaccines, and European countries say that richer nations should begin exporting more of their vaccine supply to poorer ones.

The European Union — whose approval is needed for any waiver of vaccine patents — said on Thursday that it would consider the Biden administration’s proposal. But Germany, the bloc’s largest economy, said that pushing pharmaceutical companies to share vaccine patents could have “significant implications” for the production of vaccines.

“The limiting factor in vaccine manufacturing is production capacity and high-quality standards, not patents,” a spokeswoman for Chancellor Angela Merkel of Germany said in a statement.

On Friday, Canada shared similar concerns. “Our government firmly believes in the importance of protecting intellectual property and recognizes the integral role that industry has played in innovating to develop and deliver lifesaving Covid-19 vaccines,” the minister of small businesses, Mary Ng, said in a statement.

She added many barriers to vaccine access, like supply shortages, were unrelated to intellectual property.

The European Commission president, Ursula von der Leyen, said the bloc was “ready to discuss any proposals that address the crisis in an effective and pragmatic manner.”

She also suggested, however, that the focus should be on getting more vaccines to countries that needed them by following the bloc’s example in allowing significant exports of doses. The United States has balked at that approach, keeping most doses produced domestically for use at home.

“We call upon all vaccine-producing countries to allow export and to avoid measures that disrupt the supply chains,” Ms. von der Leyen said.

The European statements emphasized the challenges of winning E.U. support for the waivers at the World Trade Organization, where the bloc wields significant influence, and where unanimous approval would be needed for any measure to suspend patents.

Many experts believe that the waivers are needed to expand the manufacturing of vaccines and get them to poorer parts of the world where inoculations have far lagged behind those of richer countries.

Until the Biden administration’s announcement this week, the United States had been a major holdout at the W.T.O. over a proposal by India and South Africa to suspend some intellectual property protections. The move could give drugmakers access to the trade secrets of how the vaccines are made.

The pharmaceutical industry has argued that suspending patent protections would undermine risk-taking and innovation.

“Who will make the vaccine next time?” Brent Saunders, the former chief executive of Allergan, which is now part of AbbVie, wrote on Twitter.

But Stephane Bancel, the chief executive of Moderna, told investors on Thursday, “We saw the news last night, and I didn’t lose a minute of sleep.”

Mr. Bancel said his company never planned to enforce the patent because few, if any, other drug makers can easily manufacture mRNA, the genetic script that carries DNA instructions to each cell’s protein-making machinery.

The debate arises amid a growing divide between wealthy nations that are slowly regaining normal life, and poorer countries that are confronting new and devastating outbreaks.

In India, which is suffering the world’s worst outbreak since the start of the pandemic, only 2.2 percent of the population is fully vaccinated, according to a New York Times database. South Africa has fully vaccinated less than 1 percent of its people. By contrast, vaccinations are slowing down in the United States — where one-third of people are fully inoculated — as they begin to pick up in Europe.

If the European Union agrees to support patent waivers, it would take months for developing nations to see the impact. Ngozi Okonjo-Iweala, the head of the W.T.O., told The Washington Post that she would press member countries to reach an agreement by Dec. 3.

Even if a waiver receives support from the trade body, it alone would not increase the world’s vaccine supply. Large drug manufacturers in India and elsewhere would need extensive technological and other support to produce doses, experts say.

Lifting intellectual property protections “is only one element,” said Anant Bhan, a health researcher at Melaka Manipal Medical College in southern India. Because of the additional steps required to begin making a vaccine on a huge scale, he said, “it is not going to mean increased access to vaccines in the near future.”

The American jobs engine slowed markedly last month, confounding rosy forecasts of the pace of the recovery and sharpening debates over how best to revive a labor market that was severely weakened by the coronavirus pandemic.

Employers added 266,000 jobs in April, the government reported Friday, far below the vigorous gains registered in March. The jobless rate rose slightly to 6.1 percent, as more people rejoined the labor force.

5

10

15%

’06

’08

’10

’12

’14

’16

’18

’20

6.1%

RECESSION

“It turns out it’s easier to put an economy into a coma than wake it up,” Diane Swonk, chief economist for the accounting firm Grant Thornton, said of the disappointing report. “It’s understandable, it’s going to take some time, you’re not just going to snap your fingers and get everyone back to work,

Economists had forecast an addition of about a million jobs. The increase for March was revised down to 770,000 from 916,000.

The Alliance for American Manufacturing blamed supply chain problems for the loss of 18,000 jobs in that sector, noting in particular the impact that a shortage of semiconductors has had on the automotive industry.

And many offices are not yet ready to reopen fully. “I just think it takes a while for businesses to figure out how many people they need,” Ms. Swonk said, noting there is still a lot of skittishness on the part of employers and workers. “I don’t view this as terribly troubling or distressing.”

Ben Herzon, executive director of U.S. economics at the financial services company IHS Markit, agreed. “A single report with unexpected weakness in job gains is not a cause for concern,” he said. “Demand is picking up, activity is picking up.”

He noted that labor force participation had been on the upswing for two months in a row, rising to 61.7 percent last month from 61.4 percent in February.

More opportunities are bubbling up as coronavirus infections ebb, vaccinations spread, restrictions lift and businesses reopen. Job postings on the online job site Indeed are 24 percent higher than they were in February last year.

“There’s been a broad-based pickup in demand,” said Nick Bunker, who leads North American economic research at the Indeed Hiring Lab. The supercharged housing market is driving demand for construction workers. There is also an abundance of loading, stocking and other warehousing jobs — a side-effect of the boom in e-commerce.

The economy still has a lot of ground to regain before returning to prepandemic levels. Millions of jobs have vanished since February 2020, and the labor force has shrunk.

–20

–15

–10

–5 million

April

June

Sept.

Jan. ’21

–8.2 million since February 2020

152.5 million jobs in February 2020

As the economy fitfully recovers, there are divergent accounts of what’s going on in the labor market. Employers, particularly in the restaurant and hospitality industry, have reported scant response to help-wanted ads. Several have blamed what they call overly generous government jobless benefits, including a temporary $300-a-week federal stipend that was part of an emergency pandemic relief program.

But there are other forces constraining the return to work. Millions of Americans have said that health concerns and child care responsibilities — with many schools and day care centers not back to normal operations — have prevented them from returning to work. Millions of others who are not actively job hunting are considered on temporary layoff and expect to be hired back by their previous employers once more businesses reopen fully. At the same time, some baby boomers have retired or switched to working part time.

An 18-year-old student received a shot of a coronavirus vaccine in Los Angeles last month.
Credit…Etienne Laurent/EPA, via Shutterstock

A series of vaccine developments and the loosening of restrictions amid an improving virus trajectory may foreshadow a welcome return to normalcy for many young Americans, just as summer vacation nears.

By early next week, the Food and Drug Administration is expected to issue an emergency use authorization allowing the Pfizer-BioNTech coronavirus vaccine to be used in children 12 to 15 years old, a major step ahead in the United States’ efforts to tackle Covid-19. Pfizer also expects to seek federal clearance in September to administer the vaccine to children age 2 to 11, the company said on Tuesday.

Vaccinating children is key to raising the level of immunity in the population, experts say, and to bringing down the numbers of hospitalizations and deaths. It could also put school administrators, teachers and parents at ease if millions of adolescent students become eligible for vaccination before the next academic year begins.

The move would be a major leap forward, experts say, and comes as the director of the Centers for Disease Control and Prevention, Dr. Rochelle Walensky, said that vaccinated adolescents would be able to remove their masks outdoors at summer camps.

Yet the eagerness of parents to let their children be vaccinated is limited, according to a new national poll, which found that three in 10 parents surveyed said they would get their children vaccinated right away and 26 percent said they wanted to wait to see how the vaccine was working. About 23 percent said they would definitely not get their children vaccinated, and 18 percent said they would do so only if a child’s school required it. The survey also noted that only 9 percent of respondents said they had not yet gotten a shot but still intended to do so, one more indication that achieving widespread immunity in the United States is becoming increasingly challenging.

As health experts focus on the future of vaccinating children, a growing number of students have returned to in-person learning this school year. In March, 54 percent of K-8 schools were open for full-time in-person learning, and 88 percent were open for either full-time in-person and/or hybrid learning, according to data from a federal government survey released on Thursday. But Black, Hispanic and Asian students are enrolled in full-time in-person learning at much lower rates than white students.

The Biden administration has made an aggressive push for reopening schools in recent months, including an effort to prioritize vaccinations for teachers and employees.

Administering the AstraZeneca vaccine in Nottingham, England, last month.
Credit…Oli Scarff/Agence France-Presse — Getty Images

Britain’s vaccines regulator advised on Friday that all adults under 40 in the country should be offered alternatives to AstraZeneca’s Covid-19 vaccine. It factored in concerns over very rare blood clots, the dwindling risk of severe coronavirus infection in younger adults and the availability of alternatives.

The guidance extends earlier advice that people under 30 would be offered alternative doses.

The use of the AstraZeneca vaccine has been marred by uncertainty after reports of a possible link between the doses and very rare blood clots, but public health experts around the world say that the vaccine’s benefits far outweigh the risks for most people.

Britain’s Joint Committee on Vaccination and Immunization stressed that the chances of younger people becoming seriously ill with the coronavirus had grown smaller as infection rates decrease across the country. It said that this new reality paired with the availability of alternative vaccines had factored into the decision.

But the country is also closely monitoring new variants of the coronavirus, and on Friday public health officials in England noted that a variant first detected in India was now considered a “variant of concern” — meaning that it is at least as transmissible as the dominant variant in Britain. The cases identified in the country more than doubled from 202 to 520 in the week, but still account for just a fraction of the cases there.

While there is still not enough evidence to indicate whether any of the variants recently detected in India cause more severe illness or render vaccines any less effective, Britain is proceeding with caution. Most of the identified cases of the variant are in London and in the town of Bolton in the northwestern England.

Regarding the AstraZeneca vaccine, the regulator advised that where available, an alternative should be offered to healthy adults under 40, though it stressed that potentially severe side effects from the doses were “extremely rare.” It noted that “for the vast majority of people, the benefits of preventing serious illness and death far outweigh any risks.”

The vaccination committee advised that anyone who received a first dose of the AstraZeneca vaccine should still receive a second, except those who experienced clotting.

Britain’s medicines regulatory agency had received reports of 242 cases of blood clots accompanied by low platelet counts in people who received the AstraZeneca vaccine through April 28. As of that date, about 22.6 million AstraZeneca doses had been administered in Britain, including about 5.9 million second doses.

Over all, about 35 million people in the country have received at least one dose of a coronavirus vaccine.

An airplane landing at the airport in Frankfurt, Germany.
Credit…Michael Probst/Associated Press

One returning pilot lost control of an aircraft during landing and skidded off the runway into a ditch. Another just returning from furlough forgot to activate a critical anti-icing system designed to prevent hazards in cold weather. Several others flew at the wrong altitudes, which they attributed to distractions and lapses in communication.

In all of these incidents, which were recorded on NASA’s Aviation Safety Reporting System, a database of commercial aviation mistakes that are anonymously reported by pilots and other airline crew, the pilots involved blamed the same thing for their mistakes: a lack of practice flying during the pandemic.

In 2020, global air passenger traffic experienced the largest year-on-year decline in aviation history, falling 65.9 percent compared with 2019, according to the International Air Transport Association. Flights were grounded, schedules reduced and thousands of pilots were laid off or put on furlough for up to 12 months.

As vaccination programs pick up speed across some parts of the world and travel starts to rebound, airlines are beginning to reactivate their fleets and summoning pilots back as they prepare to expand their schedules for the summer. But returning pilots can’t just pick up where they left off.

“It’s not quite like riding a bike,” said Joe Townshend, a former pilot for Titan Airways, a British charter airline, who was laid off when the pandemic hit in March last year.

“You can probably go 10 years without flying a plane and still get it off the ground,” he said, “but what fades is the operational side of things.”

Marc Johnson, a virologist at the University of Missouri, examining samples of wastewater to track the coronavirus.
Credit…MichaelB Thomas for The New York Times

Although Covid-19 is primarily a respiratory disease, research conducted early in the pandemic revealed that people infected with the coronavirus often shed it in their stool. This finding, combined with the scale and urgency of the crisis, spurred immediate interest in tracking the virus by sampling wastewater.

In the past year, many scientists have been drawn into the once niche field of wastewater epidemiology. Researchers in 54 countries are tracking the coronavirus in sewage, according to the Covid19Poops Dashboard, a global directory of the projects.

These teams have found that the wastewater data seemed to accurately indicate what was happening in society. When the number of diagnosed Covid-19 cases in an area increased, more coronavirus appeared in the wastewater. Levels of the virus fell when areas instituted lockdowns and surged when they reopened.

Several teams have also confirmed that sewage can serve as an early warning system: Wastewater viral levels often peaked days before doctors saw a peak in official Covid-19 cases.

And wastewater analysis has allowed scientists to detect the arrival of certain variants in a region weeks before they are found in people — and to identify mutations that have not yet been detected in people anywhere.

The surveillance is not a replacement for clinical testing, experts said, but can be an efficient and cost-effective complement. The approach is likely to be especially valuable in low- and middle-income countries, where testing resources are more limited.

“Not every population gets tested, not everyone has access to health care,” said Dr. Marc Johnson, a virologist at the University of Missouri. “If there’s groups of people that are asymptomatic, they probably aren’t getting tested either. So you aren’t really getting the full big picture. Whereas for our testing, everyone poops.”

global roundup

Australian residents at the Sydney airport last year, returning from India.
Credit…Bianca De Marchi/EPA, via Shutterstock

Australia will resume repatriation flights for Australian nationals in India after May 15, Prime Minister Scott Morrison said on Friday.

The resumption will end a travel ban that made it a criminal offense for citizens and residents of Australia to enter the country from India. No other democratic nation has issued a similar ban on all arrivals.

Australians who test positive for the coronavirus will not be allowed to travel, officials said, and the government has introduced a pre-departure testing regime in India in an effort to catch infections before they reach Australia.

Critics of the travel ban have accused the government of racism and insensitivity, but officials have said that the restrictions are necessary to prevent transmission from the devastating outbreak in India.

Australian officials initially said that anyone trying to return from India faced up to five years in prison and nearly 60,000 Australian dollars ($46,300). But as the measure came under withering criticism this week, Mr. Morrison said it was “highly unlikely” that those seeking to return home would actually face jail.

In other news from around the world:

View Source

Pfizer Seeks Full FDA Approval for Its Covid-19 Vaccine

Pfizer and the German company BioNTech have become the first companies to apply to the U.S. Food and Drug Administration for full approval of their Covid-19 vaccine for use in people 16 and older. The vaccine is currently being administered to adults in America under an emergency use authorization granted in December.

The approval process is likely to take months.

The companies said in a statement on Friday that they had submitted their clinical data, which includes six months of information on the vaccine’s safety and efficacy, to the F.D.A. They plan to submit additional material, including information about the manufacturing of the vaccine, in the coming weeks.

“We are proud of the tremendous progress we’ve made since December in delivering vaccines to millions of Americans, in collaboration with the U.S. government,” Dr. Albert Bourla, Pfizer’s chief executive, said in the statement. “We look forward to working with the F.D.A. to complete this rolling submission and support their review, with the goal of securing full regulatory approval of the vaccine in the coming months.”

As of Thursday, more than 134 million doses of the vaccine had been administered in the United States, according to the Centers for Disease Control and Prevention. Full approval would allow Pfizer and BioNTech to market the vaccine directly to customers.

said in December that employers could mandate vaccination, and legal experts have generally agreed.

Many companies have been hesitant to require the vaccines, especially while they have only emergency authorization, which is designed to be temporary. Some institutions, like the University of California and California State University systems, have said that they would do so only after a vaccine has full approval.

Full approval could also prompt the U.S. military, which has had low uptake of Covid-19 vaccines, to mandate vaccinations for service members.

If the F.D.A. grants full approval, it could also help raise confidence in the vaccine. The pace of vaccination has slowed in the United States in recent weeks, and a recent national survey indicated that most people in the country who planned to get the shots had already done so.

The agency is also expected to issue an emergency authorization for use of the Pfizer-BioNTech vaccine in 12- to 15-year-olds next week. The companies have said that they plan to file for emergency authorization for 2- to 11-year-olds in September.

Moderna plans to apply for full approval for its Covid-19 vaccine this month, the company said during its quarterly earnings call on Thursday.

View Source

New studies suggest that vaccines can protect against some variants and severe Covid cases.

Several new studies released on Wednesday offered encouraging news about the ability of widely used vaccines to protect against severe Covid-19 cases, including illness caused by some dangerous variants.

Two published studies found that the Pfizer-BioNTech vaccine was extraordinarily effective against severe disease caused by two variants, including the dominant one in the United States. And the results of an early-stage trial of the Moderna vaccine — though not published or vetted by scientists — suggested that a single dose given as a booster was effective against variants first identified in South Africa and Brazil, the company said.

The emergence of new variants, and whether vaccines are effective against them, is a subject of continued concern as a variant first detected in India, called B.1.617, spreads across the country. There is also a risk that further variants will arise there as the country’s outbreak grows, experts say. Another worrisome variant, P.1, is wreaking havoc across South America.

In the Pfizer studies, which were based on real-world use of the vaccine in Qatar and Israel, the two variants of focus were B.1.1.7, first identified in Britain and now detected in over 100 countries, and B.1.351, first identified in South Africa. The studies showed that the vaccine can prevent some of the most severe outcomes from Covid-19, such as pneumonia and death, caused by those variants.

One of the Pfizer studies showed that the vaccine was 87 to 89.5 percent effective at preventing infection with B.1.1.7 among people who were at least two weeks past their second shot. It was 72.1 percent to 75 percent effective at preventing infection with B.1.351. The study was based on information about more than 200,000 people that was pulled from Qatar’s national Covid-19 databases from Feb. 1 to March 31.

Another study, conducted by researchers at Pfizer and at Israel’s Health Ministry, found that the vaccine was more than 95 percent effective at protecting against a coronavirus infection, hospitalization and death among fully vaccinated people 16 and older.

In the United States, experts now believe that attaining herd immunity is unlikely because of the spread of variants and hesitancy among some people in the country to be vaccinated. The variant that has caused the most alarm is B.1.1.7, which is about 60 percent more transmissible than original versions of the virus.

Moderna’s announcement was greeted cautiously, because the results of an early-stage trial have not been published or peer-reviewed. But the company said it was encouraged by results that suggested that a single booster shot of its vaccine would rapidly increase antibodies in vaccinated people, and that those antibodies were effective against the original form of the virus as well as the variants first identified in South Africa and Brazil.

A second booster specifically designed to counter the variant identified in South Africa produced an even stronger immune response, the company said.

View Source

Baltimore Vaccine Plant’s Troubles Ripple Across Africa, Europe and Canada

WASHINGTON — Quality-control problems at a Baltimore plant manufacturing Covid-19 vaccines have led health officials on three continents to pause the distribution of millions of Johnson & Johnson doses, as the troubles of a politically connected U.S. contractor ripple across the world.

Doses made at the plant owned by Emergent BioSolutions have not been cleared by the Food and Drug Administration for use in the United States, and the Biden administration has repeatedly assured Americans that none of the Johnson & Johnson shots administered domestically were made there.

But millions of doses have been shipped abroad, including to Canada, the European Union and South Africa. Regulators in various countries are now working to ensure that those doses are safe after the disclosure in March that workers at the Baltimore plant accidentally contaminated a batch of Johnson & Johnson’s vaccine with the harmless virus used to manufacture AstraZeneca’s. Both vaccines were produced at the same site. The mistake forced Emergent to throw out up to 15 million Johnson & Johnson doses after tests showed that the batch failed to meet purity requirements.

E.U. officials, as well as those in Canada and South Africa, said there was no evidence that any of the doses they had received were tainted. But the problems identified in Baltimore have slowed their vaccination efforts while they perform additional quality assessments as a precaution.

said they would “not allow the release of any product until we feel confident that it meets our expectations for quality.” The plant is still finishing batches of vaccine that were already in process.

previously acknowledged that it had allowed doses of AstraZeneca’s Covid-19 vaccine made at the same Emergent plant to be sent to Canada and Mexico but said it had not attested to their quality, instead leaving that assessment to the company and authorities in both countries. Unlike the Johnson & Johnson vaccine, the AstraZeneca vaccine is not approved for use in the United States.

The Times reported last month that Emergent had discarded five lots of AstraZeneca vaccine — each the equivalent of two million to three million doses — between October and January because of contamination or suspected contamination at the same Bayview plant in Baltimore.

The European Union’s drug regulator, the European Medicines Agency, said in a statement to The Times that one batch of vaccine manufactured at the Emergent facility “is being used” after “a thorough testing of the batch and a review of the controls in place at the manufacturing site.” There is no indication of any problems with those doses.

That batch was distributed for use in the European Union only after meeting “the rigorous quality standards of our company and the European Medicines Agency,” Johnson & Johnson said in a statement.

Two more batches, amounting to about 2.5 million doses, are on hold as regulators in Europe and the United States investigate the cause of the contamination at the Emergent plant and ensure that problems have been fixed, the E.M.A. said.

“When the investigations conclude, E.M.A. may decide on actions to prevent future contamination of batches,” the statement said.

Batches of vaccine made at Emergent are not released for bottling until they have passed required safety tests, including one designed to identify “adventitious agents” such as a virus used in the manufacture of another product. People familiar with Emergent’s processes said the tests were much the same whether the vaccine was destined for domestic or foreign use.

one of the lowest vaccination rates of any country, and the Johnson & Johnson vaccine is particularly important to the nation’s plans. Many developing countries are relying on AstraZeneca’s vaccine, but South Africa stopped using it in February after a trial indicated that it was less effective against the dominant coronavirus variant then circulating in the country.

Under its contract with Johnson & Johnson, Emergent manufactured the active ingredient for the vaccine in bulk, and the substance was then sent to other facilities for final processing and packaging. One of the sites performing these final manufacturing stages is a plant run by the South African company Aspen Pharmacare. Johnson & Johnson announced in March that the site would support the company’s pledge to provide vaccine to countries throughout Africa.

The Canadian regulatory authority, Health Canada, said in a statement that officials were working with Johnson & Johnson and the F.D.A. to perform further assessments of vaccine manufactured at the Emergent facility and that the doses “will only be released for distribution once Health Canada is satisfied that they meet the Department’s high standards for quality, safety and efficacy.”

The newly disclosed delays underscore the global impact of the problems at the Baltimore factory operated by Emergent, a government contractor known for its aggressive lobbying and political connections.

As The Times previously reported, the federal government last year banked on Emergent to be the main domestic manufacturer for both the Johnson & Johnson and AstraZeneca vaccines even as evidence of serious quality problems mounted.

announced “significant revenue growth and corresponding profitability” for the first quarter of this year and projected record revenues for 2021, driven largely by the company’s Covid-19 vaccine manufacturing deals.

Emergent built a profitable business largely by cornering the market for biodefense products, a Times investigation found. Throughout most of the last decade, sales of the company’s anthrax vaccines accounted for nearly half of the annual budget of the nation’s emergency medical reserve, the Strategic National Stockpile, leaving the federal government with less money to buy supplies needed in a pandemic.

Emergent has repeatedly touted its influence in Washington in presentations to investors. Six of its 10 board members have previously served in government, and since 2010, the company has spent an average of $3 million a year on lobbying — far outspending similarly sized biotech firms, and roughly matching the outlays of some larger pharmaceutical companies.

Matina Stevis-Gridneff contributed reporting from Brussels and Ian Austen from Ottawa.

View Source

Jobless Claims Continue to Fall: Live Updates

filed first-time applications for state jobless benefits, the Labor Department said Thursday, down more than 100,000 from a week earlier. In addition, 101,000 people filed for Pandemic Unemployment Assistance, a federal program covering freelancers, self-employed workers and others who don’t qualify for regular benefits. Neither figure is seasonally adjusted.

Applications for unemployment benefits remain high by historical standards, but they have fallen significantly in recent weeks after progress stalled in the fall and winter. Weekly filings for state benefits, which peaked at more than six million last spring, fell below 700,000 for the first time in late March and has now been below that level for four straight weeks.

“In the last few weeks we’ve seen a pretty dramatic improvement in the claims data, and I think that does signal that there’s been an acceleration in the labor market recovery in April,” said Daniel Zhao, senior economist at the employment site ZipRecruiter.

Economists should get a clearer picture of the labor market’s progress on Friday when the Labor Department will release data on hiring and unemployment in April. The report is expected to show that employers added about one million jobs last month, up from 916,000 in March. The leisure and hospitality industry, which was hardest hit by the initial phase of the pandemic last spring, has led the way in the recovery in recent months, a trend that forecasters believe continued in April.

Many employers have said in recent weeks that they would like to hire even faster but have struggled to find enough workers. Some have blamed enhanced unemployment benefits for discouraging people from returning to work. On Tuesday, Gov. Greg Gianforte of Montana said his state would pull out of a federal program offering enhanced benefits to unemployed workers and would instead pay a $1,200 bonus to recipients when they find new jobs.

Economic research has found that unemployment benefits can reduce the intensity with which workers search for jobs. But most studies find that the impact on the overall labor market is small, especially when unemployment is high. And Mr. Zhao and other economists say there are other reasons that labor supply might be rebounding more slowly than labor demand. Many potential workers are juggling child care or other responsibilities at home; others remain cautious about the health risks of returning to in-person work.

“I think we will see labor supply improve pretty dramatically in the coming months as the pandemic abates,” Mr. Zhao said.

The Bank of England in London. Policymakers forecast unemployment in Britain to peak at 5.5 percent later this year, thanks to the extension of the government’s furlough program.
Credit…Matt Dunham/Associated Press

The Bank of England unveiled a much brighter outlook for the British economy on Thursday, saying it would return to its prepandemic levels at the end of this year as lockdowns ended, consumers spent billions of pounds in extra savings and the vaccine rollout reduced public health worries.

The central bank, in its quarterly monetary report, raised its growth forecasts and slashed its predictions for unemployment. The British economy is now projected to grow 7.25 percent this year, compared to a forecast of 5 percent growth three months ago. This would be the fastest pace of expansion for the economy since official records began in 1949, pulling Britain out of its worst recession in three centuries.

The higher forecast comes after the government has announced tens of billions of pounds in additional spending to see workers and businesses through the summer, and outlined its plan to end lockdown restrictions by late June.

Britain’s economic output “recovers strongly over the course of 2021, albeit only back to pre-Covid levels,” Andrew Bailey, the governor of the Bank of England, said in a news conference on Thursday.

“Of course, there remains uncertainty around how the pandemic might evolve and so there are risks around this projection, including from renewed waves of infections in the U.K. and other countries,” he said.

He added that there was also an “enormous amount of uncertainty” about how the pandemic might permanently change people’s working and living patterns, and the effect that will have on the shape of the economy.

Even though inflation is expected to rise above the central bank’s 2 percent target, policymakers voted unanimously to keep the benchmark interest rate at 0.1 percent. It cut rates to that level in March 2020 at the start of the coronavirus pandemic.

The central bank also said it would slow the pace of its £875 billion government bond-buying program, which was projected to run through 2021, so that it does not finish the program before the end of the year. If the central bank had continued at its current pace, the buying program would have ended several months early. Instead of buying £4.4 billion government bonds a week, the central bank will buy £3.4 billion. The program helps keep government borrowing costs low and supports the economy by encouraging investors to buy other assets.

The minutes of the central bank’s policy meeting showed that officials don’t intent to tighten monetary policy until “there is clear evidence that significant progress” is made on the economic recovery and inflation is sustainably at the bank’s target.

The Bank of England now forecasts unemployment to peak at 5.5 percent later this year, because of the extension of the government’s furlough program. In February, the central bank predicted the unemployment rate would rise as high as 7.75 percent.

The easing of pandemic restrictions will also increase consumer spending. The central bank added that it now expected people to spend about 10 percent of the excess savings they built up in lockdown based on new survey evidence. The previous estimate was just 5 percent.

But these extra savings are “not evenly distributed,” Mr. Bailey said. And they are concentrated among people who are older and already wealthier.

Gary Gensler, Chairman of the Securities and Exchange Commission.
Credit…Kayana Szymczak for The New York Times

Gary Gensler, the newly installed chair of the Securities and Exchange Commission, is testifying on Thursday, at noon Eastern time, before the House Financial Services Committee. He will address the meme-stock volatility in January that led to trading restrictions and prompted an outcry about Wall Street’s relationship with retail investors.

“I think these events are part of a larger story about the intersection of finance and technology,” Mr. Gensler will say in his prepared remarks, highlighting seven factors at play that also hint at his regulatory priorities in the months ahead:

Volkswagen’s display at the Shanghai auto show in China last month. China is the German carmaker’s largest market.
Credit…Aly Song/Reuters

A spike in sales to Chinese customers helped Volkswagen rebound strongly from the disruption caused by the pandemic, the carmaker said Thursday, underlining China’s importance to the German economy.

Sales in the first three months of 2021 rose 13 percent compared to a year earlier, to 62.4 billion euros, or $75 billion, while profit rose nearly sevenfold to 3.4 billion euros, the company said. Vehicle sales in China, which is Volkswagen’s largest market, rose more than 60 percent.

The recovery in sales bodes well for the German economy. Vehicles are the country’s biggest export product. But Volkswagen also illustrates Germany’s dependence on China when tensions between Beijing and the European Union are rising because of the Chinese government’s treatment of minority groups and its crackdown on dissent in Hong Kong.

As is typical for Volkswagen, the company’s Audi and Porsche divisions generated most of the profit. The luxury vehicles have a higher profit margin than the more affordable cars that account for most of Volkswagen’s volume.

Volkswagen said it was able to manage the shortage of semiconductors that has afflicted all carmakers in recent months, but warned that the chip famine could become more acute in months to come.

Volkswagen sold 60,000 battery-powered vehicles out of a total of 2.4 million during the quarter. That may be a disappointment to the company, which has staked its future on a new line of electric cars, the first of which went on sale late in 2020.

A coronavirus testing center in Soweto, South Africa. The World Trade Organization is considering a proposal to provide drugmakers around the world access to the patents behind coronavirus vaccines.
Credit…Joao Silva/The New York Times
A Eurostar train in London’s St. Pancras International station in December. As an independent train operator, Eurostar isn’t eligible for direct state aid.
Credit…Suzie Howell for The New York Times

Consider it a small victory.

Eurostar, the sleek and speedy high-speed train service that ties London, Paris, Brussels, Amsterdam and other cities, will increase as of May 27 its timetable to two trains per day on its once heavily-traveled Paris-London route, up from just one round-trip train per day imposed during the pandemic.

The slightly increased service comes as governments in Europe plan to slowly lift longstanding national restrictions on travel designed to combat the spread of the virus. From a peak of running more than 60 trains a day, Eurostar cut service during the pandemic to one daily round-trip between London and Paris, and one on its London-Brussels and Amsterdam routes.

The Brussels/Amsterdam route will remain the same with one train in each direction per day, a spokesman said, adding that Eurostar will adapt its timetable should demand increase, which still depends on travel restrictions across its routes.

Eurostar’s future has been thrown into turmoil as pandemic measures led last year to a 95 percent slump in ridership, creating a cash crunch and pushing the iconic company to the brink of bankruptcy.

While some airlines and other tourist-related businesses in Europe have been able to rely on government support during the crisis, Eurostar, an independent train operator, isn’t eligible for direct state aid.

Last month, the company, which is now owned by a consortium that includes the French and Belgium national railways, reportedly secured a deal with its lenders to refinance a debt pile worth £400 million ($553 million). The British government, which in 2015 sold its stake in the rail company, last month declined to back a broader financial rescue package.

A spokesman for Eurostar said it had no new details on a financial rescue, but said that “conversations are still progressing.” The spokesman added that it is “too early to predict a recovery to prepandemic levels, this would be very much dependent on the easing of international travel restrictions which are yet to be confirmed.”

Eurostar trains will continue to maintain some vacant seats onboard to allow for social distancing. The company said it is advising riders to check with their embassies before traveling, and to consult the company’s website for the latest information.

Tim Lorentz with the LaBoata in Spokane, Wash.
Credit…Allie Lorentz

Tim Lorentz, a special-education teacher in Spokane, Wash., loves both cars and boats. He has raced cars and has owned a variety of muscle and exotic vehicles.

“Car guys always want to own or drive a unique car that no one else owns,” Mr. Lorentz said. “I created an eight-passenger convertible. Why not a boat mounted over a convertible? I have never seen another one like it.”

And so the LaBoata was born. Mr. Lorentz, now 65, built it in 2009 using a white 1993 LeBaron a used 17-foot boat he got for $100, Mercedes Lilienthal reports for The New York Times.

The LaBoata was “instant fun,” he said, until he received a letter from the Washington Department of Motor Vehicles canceling his registration and title. The authorities had noticed his converted convertible, and they weren’t amused. He removed the boat shell, drove the car to the D.M.V. and had it reinspected, reinstated and relicensed. He went home and popped the boat back on, and he has had no issues since.

Mr. Lorentz is part of a community that builds cars out of scrap. Kelvin Odartei Cruickshank, who is 19 and lives in Accra, Ghana’s capital city, built, from scratch, a two-person car that looks like a ramshackle DeLorean. It took three years to complete. Mr. Cruickshank used about $200 of scrap metal and parts not normally used in cars because of financial constraints.

View Source

Covid-19 Live Updates: Vaccines Protect Against Some Variants, Studies Show

vaccine was extraordinarily effective against severe disease caused by two variants, including the dominant one in the United States. And the results of an early-stage trial of the Moderna vaccine — though not published or vetted by scientists — suggested that a single dose given as a booster was effective against variants first identified in South Africa and Brazil, the company said.

The emergence of new variants, and whether vaccines are effective against them, is a subject of continued concern as a variant first detected in India, called B.1.617, spreads across the country. There is also a risk that further variants will arise there as the country’s outbreak grows, experts say. Another worrisome variant, P.1, is wreaking havoc across South America.

In the Pfizer studies, which were based on real-world use of the vaccine in Qatar and Israel, the two variants of focus were B.1.1.7, first identified in Britain and now detected in over 100 countries, and B.1.351, first identified in South Africa. The studies showed that the vaccine can prevent some of the most severe outcomes from Covid-19, such as pneumonia and death, caused by those variants.

“At this point in time, we can confidently say that we can use this vaccine, even in the presence of circulating variants of concern,” said Dr. Annelies Wilder-Smith, a researcher in infectious diseases at the London School of Hygiene and Tropical Medicine.

One of the Pfizer studies showed that the vaccine was 87 to 89.5 percent effective at preventing infection with B.1.1.7 among people who were at least two weeks past their second shot. It was 72.1 percent to 75 percent effective at preventing infection with B.1.351. The study was based on information about more than 200,000 people that was pulled from Qatar’s national Covid-19 databases from Feb. 1 to March 31.

Another study, conducted by researchers at Pfizer and at Israel’s Health Ministry, found that the vaccine was more than 95 percent effective at protecting against a coronavirus infection, hospitalization and death among fully vaccinated people 16 and older.

In the United States, experts now believe that attaining herd immunity is unlikely because of the spread of variants and hesitancy among some people in the country to be vaccinated. The variant that has caused the most alarm is B.1.1.7, which is about 60 percent more transmissible than original versions of the virus.

Moderna’s announcement was greeted cautiously, because the results of an early-stage trial have not been published or peer-reviewed. But the company said it was encouraged by results that suggested that a single booster shot of its vaccine would rapidly increase antibodies in vaccinated people, and that those antibodies were effective against the original form of the virus as well as the variants first identified in South Africa and Brazil.

A second booster specifically designed to counter the variant identified in South Africa produced an even stronger immune response, the company said.

A vaccination center at a school in New Delhi on Wednesday. 
Credit…Tauseef Mustafa/Agence France-Presse — Getty Images

As India recorded a single-day high in new coronavirus cases on Thursday, its vaccination campaign has been marred by shortages and states are competing against one another to get doses, limiting the government’s hope that the country can soon emerge from a devastating outbreak.

The Indian health ministry recorded about 410,000 cases in 24 hours, a new global high, and 3,980 deaths, the highest daily death toll in any country outside the United States. Experts believe the number of actual infections and deaths is much higher.

A second wave of infections exploded last month, and some Indian states reintroduced partial lockdowns, but daily vaccination numbers have fallen. The government said it had administered nearly two million vaccine doses on Thursday, far lower than the 3.5 million doses a day it reached in March. Over the past week, 1.6 million people on average were vaccinated daily in the country of 1.4 billion.

India’s pace of vaccinations has become a source of global concern as its outbreak devastates the nation and spreads into neighboring countries, and as a variant first identified there begins to be found around the world. The outbreak has prompted India to keep vaccine doses produced by its large drug manufacturing industry at home instead of exporting them, slowing down vaccination campaigns elsewhere.

In an effort to make doses more widely available within India, the authorities have allowed states and private health care providers to buy vaccines directly from manufacturers. But that has left state governments competing with one another for doses, and experts say it has added more troubles to a sluggish rollout. The authorities in Delhi, the capital, and several states have said they had to delay the expansion of vaccine access to younger age groups because of shortages.

India also lacks enough doses to meet the growing demand. Two domestic drug companies — the Serum Institute of India, which is manufacturing the vaccine developed by AstraZeneca, and Bharat Biotech, which is making its own vaccine — are producing fewer than 100 million doses per month.

About 3 percent of India’s population has been fully vaccinated, and 9.2 percent of people have received at least one dose. Experts say that at the current rate the country is unlikely to meet Prime Minister Narendra Modi’s target of inoculating 300 million people by August.

India has recorded 20.6 million coronavirus cases and more than 226,000 deaths, according to a New York Times database.

India’s government has said it will fast-track approvals of foreign-made vaccines, and on Wednesday the Biden administration said it would support waiving intellectual property protections for Covid-19 vaccines to increase supplies for lower-income countries.

But a waiver would need to win unanimous support at the World Trade Organization — and even then, experts say, India’s drug companies would need extensive technological and other support to produced doses.

“The drop in I.P. protections is only one element,” Anant Bhan, a health researcher at Melaka Manipal Medical College in southern India, said of intellectual property. Because of the additional steps required to begin making a vaccine on a huge scale, he said, “it is not going to mean increased access to vaccines in the near future.”

As Mr. Modi has declined to impose a nationwide lockdown like the one he brought in last year, states have adopted their own measures. On Thursday, the southern state of Kerala, which has one of the highest caseloads, announced a near-total lockdown until May 16.

Experts also worry that a crisis may be unfolding in India’s rural areas, where testing capacities are even more limited.

“My main concern is nonavailability of testing and the logistics of not getting people tested in rural areas,” said Gautam Menon, a professor of physics and biology at Ashoka University in northern India. “So we will never get the real numbers for either infection rates or deaths from many such quarters of India.”

The U.S. State Department has approved the departure of family members of U.S. government employees in India and is urging American citizens to take advantage of commercial flights out of the country. It said on Wednesday that it would approve the voluntary departure of nonemergency U.S. government employees.

On Thursday, Sri Lanka became the latest country to bar travelers from India, joining the United States, Britain, Australia and others.

The European Union is one of the world’s largest producers, exporters and consumers of vaccines.
Credit…Alessandro Grassani for The New York Times

The European Union is considering whether to follow the Biden administration’s decision to support a waiver of patent rights for Covid-19 vaccines as many poor and middle-income nations struggle to secure lifesaving doses.

The European Commission’s president, Ursula von der Leyen, stopped short of outright supporting President Biden in a speech on Thursday morning, but said the European Union was “also ready to discuss any proposals that address the crisis in an effective and pragmatic manner.”

“That is why we are ready to discuss how the U.S. proposal for a waiver on intellectual property protections for Covid-19 vaccines could help achieve that objective,” she said, speaking at the Florence European University Institute.

The United States had been a major holdout at the World Trade Organization over a proposal to suspend some intellectual property protections, a move that could allow drugmakers access to the trade secrets of how the viable vaccines have been made. But President Biden had come under increasing pressure to support the proposal, which was drafted by India and South Africa.

President Emmanuel Macron of France said on Thursday that he welcomed the Biden administration’s support for waiving intellectual property protections for Covid-19 vaccines, but that the short-term priority was to donate existing doses to poorer countries rather than helping them produce the vaccines themselves.

“You can transfer the intellectual property to pharmaceutical manufacturers in Africa,” he said while visiting a vaccination center in southern Paris, but “they don’t have the platforms to produce mRNA vaccines.”

The European Union is one of the world’s largest producers, exporters and consumers of vaccines and has so far opposed activism at the W.T.O. level to recognize the pandemic as a huge emergency and remove protections on the vaccines. Doing so would allow them to ultimately be produced in larger volumes by manufacturers around the world.

Shares of some pharmaceutical companies fell on Wednesday after Mr. Biden’s announcement and continued dropping on Thursday. BioNTech shares in Germany were down about 15 percent since news of the administration’s decision. Novavax, which fell 5 percent Wednesday, fell another 3 percent in premarket trading on Wall Street.

The International Olympic Committee is moving to help athletes and officials get vaccinated before traveling to the Summer Games in Tokyo.
Credit…Hiro Komae/Associated Press

Athletes and officials traveling to the Olympic Games in Tokyo this summer will be offered doses of the Pfizer-BioNTech Covid-19 vaccine before arriving in Japan, the International Olympic Committee said on Thursday, in an effort to reassure the Japanese public about the safety of hosting the event.

The committee said it had struck a deal with the drug makers to send the doses to Olympic and Paralympic Games participants’ home countries, where they will be administered through domestic inoculation programs.

The effort is the latest attempt by Olympic officials and Japanese organizers to assuage the concerns of Japanese people who do not want their country to host the Games during the pandemic. Less than 1 percent of people in Japan have been fully vaccinated against Covid-19, according to a New York Times database, and restaurants, bars and nonessential businesses are closed in several areas, including Tokyo.

The initiative was developed “not only to contribute to the safe environment of the Games, but also out of respect for the residents of Japan,” the committee said in a statement.

Despite the move and an earlier announcement that the committee would buy doses of a Chinese-made vaccine, there is no requirement for athletes, coaches, officials and others attending the Games to be vaccinated.

In March, China said it would provide vaccines for Olympic participants. But China’s vaccines have not been approved in many countries, and several — including Japan — said they would decline the offer.

The I.O.C. president, Thomas Bach, acknowledged that accepting the vaccine was voluntary, even as he urged competitors to be inoculated. “We are inviting the athletes and participating delegations of the upcoming Olympic and Paralympic Games to lead by example and accept the vaccine where and when possible,” he said.

Dining at a restaurant in San Diego last week.
Credit…Ariana Drehsler for The New York Times

After weeks of coronavirus patients flooding emergency rooms in Michigan, hospitalizations are falling. On some recent days, entire states have reported zero new coronavirus deaths. And in New York and Chicago, officials have vowed to fully reopen in the coming weeks, conjuring images of a vibrant summer of concerts, sporting events and packed restaurants.

Americans have entered a new, hopeful phase of the pandemic as the outlook has improved across the nation. The country is recording about 49,000 new cases a day, the lowest number since early October, and hospitalizations have plateaued at about 40,000, a similar level as the early fall.

“We’re in a really good spell and we can act accordingly,” said Andrew Noymer, an epidemiologist at the University of California, Irvine, who said it made sense to loosen restrictions now, when the risk is lower than it might be this winter.

Yet even as a sense of hope spreads, there remain strong reasons for caution. Deaths are hovering around 700 a day — down from a peak of more than 3,000 in January. The pace of vaccinations in the country is slowing, and experts now believe that herd immunity in the United States may not be attainable. More transmissible variants of the virus are also spreading.

That could leave the coronavirus infecting tens of thousands of Americans and killing hundreds more each day for some time.

Although more than half of adults in the country have received at least one dose of a coronavirus vaccine, a new national poll suggests that the American public’s willingness to get a Covid-19 vaccine is reaching a saturation point.

Nine percent of unvaccinated respondents said they intended to get a shot, according to the survey, published in the April edition of the Kaiser Family Foundation’s Vaccine Monitor. And with federal authorization of the Pfizer vaccine for people age 12 to 15 expected imminently, parents’ eagerness to have their children vaccinated is also limited, the poll found.

Among the parents surveyed, three in 10 said they would have their children vaccinated immediately, and 26 percent said they wanted to wait and see how the vaccines were working. Eighteen percent said they would have their children vaccinated only if a child’s school required it, and 23 percent said they would not have their children vaccinated.

“We’re in a new stage of talking about vaccine demand,” said Mollyann Brodie, the executive vice president of Kaiser’s Public Opinion and Survey Research Program. “There’s not going to be a single strategy to increase demand across everyone who is left.”

Even so, public health experts say that while they still expect significant local and regional surges in the coming weeks, they do not think they will be as widespread or reach past peaks.

Dr. Jeffrey Duchin, the health officer in Seattle and King County, said there was no playbook for an endgame to this pandemic, but he urged people to get vaccinated.

“I’m sure all of us want to avoid a long game of Whac-a-Mole with imposing and easing restrictions,” he said. “Vaccination is the cure.”

Global Roundup

A checkpoint in Suva, Fiji, last week, after the Fijian capital entered a 14-day lockdown.
Credit…Leon Lord/Agence France-Presse — Getty Images

The police and the military in Fiji locked down a major hospital on the island of Viti Levu on Wednesday night, aiming to contain the country’s second coronavirus outbreak.

More than 400 patients and employees are inside the hospital, said Dr. James Fong, the health ministry’s permanent secretary. The lockdown was precipitated by the death of a patient in the intensive-care unit, the third known person to have died from the virus in Fiji. The virus is believed to have passed from the patient to at least two doctors.

Health workers hope to use the lockdown to determine which patients and workers might have come into contact with those infected. Officials said that those inside the hospital would be provided with food and other supplies. Sections of the hospital have been converted into intensive-care units in case other severe infections arise.

With a population of around one million, Fiji has about 50 active cases of the virus, out of 125 total cases reported since the start of the pandemic. Many of the active cases are thought to be of a coronavirus variant first discovered in India.

Recent social restrictions have often been ignored in the South Pacific island nation: The Fijian police have arrested more than 100 people for breaches, with many infractions said to be connected to alcohol or kava, a local intoxicant.

Dr. Fong said at a news conference this week that the country’s containment strategy could take months. “Every Fijian must be ready,” he said.

“We are not up against an identical enemy this time around,” Dr. Fong added. “The chains of transmission are more widespread, and the variant is more transmissible.”

In other news around the world:

A giant squid statue, made at a cost of nearly $230,000, in the town of Noto, Japan.
Credit…Noto Town, via Agence France-Presse — Getty Images

A coastal town in Japan has provoked debate after spending nearly $230,000 in federal Covid-19 relief money on a 43-foot statue of a flying squid.

Noto, a fishing town where the squid is a delicacy, erected the statue in March in a bid to promote tourism after the pandemic subsides. The five-and-a-half-ton pink sea creature sits outside a squid-themed restaurant and tourist center.

Tetsuji Shimoyachi, a town official, said he hoped the statue would be “a driving-force attraction in the post-Covid period.”

But the giant squid’s unveiling provoked questions among some of the 16,000 residents of the town, roughly 180 miles northwest of Tokyo, who wondered whether there weren’t better uses of its emergency relief funds.

One Twitter user asked how the world would view the installation of a giant squid “in a country where vaccines were not provided, P.C.R. testing isn’t increased and the medical system has collapsed.”

Mr. Shimoyachi acknowledged that residents had raised concerns about whether the money should have been spent elsewhere.

He said that of the $6.2 million in coronavirus relief that the town received from the Japanese government last year, it had spent about $2.5 million on infection control measures and $1.3 million to promote local businesses and employment, and still had money left over after purchasing the squid statue. The town has recorded fewer than 30 coronavirus cases since the pandemic began.

In all, Japan allocated $41 billion in emergency subsidies to municipalities last year to address the pandemic and its economic impact.

Mr. Shimoyachi said that Noto was historically a center of squid fishing in Japan, but that catches had significantly declined because of competition from Chinese and North Korean boats. Tourism has also fallen, which led the town to build the tourist center in a bid to attract visitors — although Mr. Shimoyachi said that it was too soon to start a marketing campaign.

Japan has controlled the virus better than many countries but has faced a recent spike in cases in Tokyo and other municipalities. The surge has prompted a new round of economic restrictions, criticism of Japan’s slow vaccine rollout and questions over whether the country should proceed with the Tokyo Olympics, which are scheduled to begin in July.

The pandemic has caused some Americans to become more spartan when it comes to bathing.
Credit…Elizabeth Cecil for The New York Times

Robin Harper, an administrative assistant at a preschool in Martha’s Vineyard, grew up showering every day. “It’s what you did,” she said.

But when the pandemic forced her indoors and away from the public, she started showering once a week. The new practice felt environmentally virtuous, practical and freeing — and it has stuck.

“Don’t get me wrong — I like showers,” said Ms. Harper, 43, who has returned to work. “But it’s one thing off my plate. I’m a mom, I work full-time, and it’s one less thing I have to do.”

The pandemic has upended the use of zippered pants and changed many people’s eating and drinking habits. And there are now indications that it has caused some Americans to become more spartan when it comes to ablutions.

Parents say that their teenage children are forgoing daily showers. After the British news media reported on a YouGov survey showing that 17 percent of people in Britain had abandoned daily showers during the pandemic, many on Twitter said they had done the same.

Heather Whaley, 49, a writer in Reading, Conn., said that her shower use had dropped 20 percent in the past year. After the pandemic forced her into lockdown, she said, she began considering why she was showering every day.

“Do I need to? Do I want to?” she said. “The act of taking a shower became less a matter of function and more of a matter of doing something for myself that I enjoyed.”

A Covid-19 patient at a hospital in Moradabad, India, on Wednesday.
Credit…Prakash Singh/Agence France-Presse — Getty Images

The calls come at all hours, sometimes 15 a day, from some of India’s most oppressed and severely ill people, buzzing a cellphone that belongs to Dolly Arjun, an Indian-American physician assistant in Boston.

A few years ago, Ms. Arjun founded a telehealth program to provide free health care to members of India’s Indigenous tribes and to Dalits, who are at the lowest rungs of India’s entrenched caste system and have long faced discrimination. Dalits are typically the last to receive assistance in humanitarian disasters and often live in impoverished rural villages with no hospitals, medical care or schools.

Now, with a devastating wave of coronavirus infections surging across India, Dalits are facing a new peril, Ms. Arjun said. She said she was desperate to help, even though she is emotionally exhausted after a year of working with Covid-19 patients in Massachusetts.

“Tons of people are dying,” Ms. Arjun said. “This is just a human to human need.”

Her focus is not just Hippocratic. She is Dalit herself, a rarity among Indian medical professionals in the United States, most of whom come from upper-caste urban families. “The only reason they might know a Dalit person is because it’s their servant at home,” Ms. Arjun said.

Her telemedicine program has health workers in India who can translate for patients in local languages, but finding medical professionals in the United States to join the effort has not been easy, she said. Still, Ms. Arjun has recruited two physicians.

Patients contact the group through WhatsApp, Facebook and YouTube, and the medical professionals call back on video. Often their first task is to reassure patients who have little understanding of the coronavirus or the appropriate medical treatments, Ms. Arjun said.

“Part of what’s happening now is patients are being told Covid is going to kill you, so they are panicked,” Ms. Arjun said.

She noted that in one Indian state the government has been broadly distributing packets of medications — including 25 days-worth of antibiotics, which cannot treat viruses — to residents, regardless of whether they have tested positive for Covid-19 or show symptoms.

Sometimes, however, the telehealth calls detect life-or-death emergencies. In late April, Ms. Arjun logged onto a WhatsApp video call with a young Dalit man and his 60-year-old father, who was at home with breathing problems in the central Indian state of Madhya Pradesh, where it was around midnight.

“They didn’t know what to do,” she said. “They told us there were no hospitals or oxygen available, and they hadn’t seen a doctor.”

After assessing the man, Ms. Arjun urged the family to check to see whether any hospital beds were available instead of assuming that they were full. “It took a lot of convincing,” she said.

The next day, he was admitted and began to improve, but the hospital was running out of oxygen. Ms. Arjun put out a call on several WhatsApp groups for an oxygen cylinder, though the family did not know the name of the hospital and then fell out of contact.

Days later, she learned that the man had died.

There were road blocks, fires and riots in southern Bogotá on Tuesday after a week of protests and strikes over tax reforms proposed by the Colombian government.
Credit…Federico Rios for The New York Times

BOGOTÁ, Colombia — A teenager shot to death after kicking a police officer. A young man bleeding out on the street as protesters shout for help. Police officers firing on unarmed demonstrators. Helicopters swarming overhead, tanks rolling through neighborhoods, explosions echoing in the streets. A mother crying for her son.

“We are destroyed,” said Milena Meneses, 39, whose only son, Santiago, 19, was killed in a protest over the weekend.

Colombians demonstrating over the past week against the poverty and inequality that have worsened the lives of millions since the pandemic began have been met with a powerful crackdown by their government, which has responded to the protests with the same militarized police force it often uses against rebel fighters and organized crime.

The clashes have left at least 24 people dead, most of them demonstrators, and at least 87 missing. They have also exacerbated the anger with officials in the capital, Bogotá. Protesters say the government is increasingly out of touch with people’s lives.

Experts say this explosion of frustration could presage unrest across Latin America, where several countries face the combustible mix of an unrelenting pandemic, growing hardship and plummeting government revenue.

“We are all connected,” said León Valencia, a political analyst, noting that past protests had jumped from country to country. “This could spread across the region.”

The marches began last week after Mr. Duque proposed a tax overhaul meant to close a pandemic-related economic shortfall, and since then the crowds have grown. Demonstrators now include teachers, doctors, students, members of major unions, longtime activists and Colombians who have never before taken to the streets.

Latin America was one of the regions hardest hit by the virus last year, with cemeteries filling past capacity, the sick dying while awaiting care in hospital hallways, and family members spending the night in lines to buy medical oxygen in an attempt to keep loved ones alive.

The region’s economies shrank an average of 7 percent. In many places, unemployment, particularly among the young, spiked. And in the first few months of 2021, the Covid-19 situation has worsened.

Travelers at Chicago O’Hare airport last week. With more people vaccinated against Covid, travel is increasing.
Credit…Spencer Platt/Getty Images

More than 106 million people in the United States are fully vaccinated. Airlines are resuming overseas flights. Come summer, fully vaccinated people traveling from America will once again be welcome across Europe.

But the reality is more sobering.

Globally, more new coronavirus cases were reported in recent weeks than at any point since the onset of the pandemic. The numbers are being driven by an uncontrolled outbreak in India, but also account for troubling trends among European destinations popular with Americans, from France and Germany to Italy and Spain.

“My doomsday scenario is a mixing of vaccinated and unvaccinated populations in a setting where there is high viral load and high viral transmission,” said Dr. Sarah Fortune, the chair of the Department of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health.

Even if international tourists could travel safely, securely and without risking the well-being of their hosts, visitors may face yet another impediment: The destinations may lack many of their usual draws. In Paris, bars and restaurants have been closed since the end of October, as are museums.

Jordyn Coleman, 11, attending math class from his apartment in Clarksdale, Miss., during a virtual learning day.
Credit…Tamir Kalifa for The New York Times

Until the pandemic, Jordyn and his mother, Precious Coleman, lived in Battle Creek, Mich., where he was known among his teachers as a bright but easily distracted student, capable of soaring when he was engaged.

On the day of a standardized test, Jordyn sat in front of his computer, humming to himself and spinning around in his chair. His teacher thought he was goofing off — until the results came in.

When his mother came to pick him up, a school administrator was waiting for her, and she worried Jordyn had gotten into trouble. “That’s when they told me that he had gotten not just the best score in his class but the best score in the entire grade,” she said.

After the pandemic hit, Ms. Coleman struggled to make ends meet. She and her two sons ended up moving to Clarksdale, Miss., one of the poorest corners of the United States. Ms. Coleman works an overnight shift at a casino. Jordyn waits for her to return home in the morning so he can log in to school with her cellphone, and she struggles to stay awake to help him.

Now Jordyn is at risk of becoming one of the lost students of the coronavirus pandemic in the most disrupted American school year since World War II.

View Source

Parents Are Reluctant to Get Their Children Vaccinated for Covid-19, Poll Shows

The American public’s willingness to get a Covid vaccine is reaching a saturation point, a new national poll suggests, one more indication that achieving widespread immunity in the United States is becoming increasingly challenging.

Only 9 percent of respondents said they hadn’t yet gotten the shot but intended to do so, according to the survey, published in the April edition of the Kaiser Family Foundation’s Vaccine Monitor. And with federal authorization of the Pfizer vaccine for adolescents ages 12 through 15 expected imminently, the eagerness of parents to let their children be vaccinated is also limited, the poll found.

Overall, slightly more than half of those surveyed said they had gotten at least one dose of the vaccine, a finding that matches data from the Centers for Disease Control and Prevention.

“We’re in a new stage of talking about vaccine demand,” said Mollyann Brodie, executive vice president of Kaiser’s Public Opinion and Survey Research Program. “There’s not going to be a single strategy to increase demand across everyone who is left. There will be have to be a lot of individually targeted efforts. The people still on the fence have logistical barriers, information needs, and lots don’t yet know they are eligible. Each strategy might move a small number of people to get vaccinated, but all together, that could matter a lot.”

With a growing number of scientists and public health experts concluding that it is unlikely that the country will reach the threshold of herd immunity, the Biden administration has stepped up efforts to reach those who are still hesitant. On Tuesday, the administration announced steps to encourage more pop-up and mobile vaccine clinics and to distribute shots to primary care doctors and pediatricians as well as local pharmacies.

The survey also showed that confidence in the Johnson & Johnson vaccine had suffered a significant blow after the 10-day pause in dispensing it while the authorities examined rare incidents of life-threatening blood clots in people who had taken it. While 69 percent of people said they had confidence in the safety of the vaccines made by Pfizer and Moderna, only 46 percent felt confident about the safety of the Johnson & Johnson vaccine. Among adults who have not been vaccinated, one in five said that the news about the Johnson & Johnson shot had prompted them to change their minds about getting a Covid-19 vaccine.

The survey did show that there had been some progress among Republicans, who have been among the firmest holdouts. Among that group, 55 percent said they had gotten a shot or intended to do so, up from 46 percent in March. The percentage who will “definitely not” get the vaccine is shrinking as well, down to 20 percent from 29 percent in March.

The results were based on telephone surveys of a nationally representative sample of 2,097 adults from April 15 through April 29.

A consortium of universities that includes Harvard, Northeastern and Rutgers has been conducting online polls during the pandemic and recently focused on parents. The group’s latest survey, conducted throughout April and reaching 21,733 adults across 50 states, found that the divide between mothers and fathers in views about the vaccine for children had widened.

Fathers are becoming more accepting, with their resistance falling to 11 percent from 14 percent since February. But over a quarter of mothers, researchers said, still say they are “extremely unlikely” to vaccinate their children. Both genders are more resistant to the vaccine for younger children than for teenagers. Other research shows that mothers tend to have more sway over the final decision than fathers.

The responses from parents may well change over time, experts say. Just as adults were far more reluctant last summer when the vaccine was still a concept, parents surveyed several weeks ago, when imminent authorization for children under 16 had not been widely discussed, might also have been reacting to a hypothetical situation rather than a reality.

But pediatricians and others who are seen as trusted sources of information are already aware that they have considerable work to do to instill vaccine confidence in this latest cohort.

Dr. Sean O’Leary, a pediatrician in Denver who is vice chairman of the committee on infectious diseases for the American Academy of Pediatrics, predicted that just as adults had swarmed Covid vaccine providers during the initial weeks of distribution, parents and pent-up young teenagers would rush for it at the start, too.

But Dr. O’Leary, who often gives talks to pediatricians about how to motivate patients to accept vaccinations, worries that a slowdown will inevitably follow. To persuade hesitant parents, he said, “we have to make the vaccine available in as many places as possible.”

He added, “If parents and patients are in the pediatrician’s office and the doctor can say, ‘Hey, I’ve got it,’ that may be enough of a nudge for them to say, ‘Let’s go ahead and do this.’”

View Source